• See Section 6 regarding identifying patients at low risk.
• The marginal benefits of nirmatrelvir-ritonavir for patients at low risk of hospitalization (those expected to have a 0.5% risk of hospital admission) suggest most patients would not want to use this treatment, but a minority may still be inclined to do so.
• The GDG noted the uncertainty in baseline risk estimates and uncertainty and variability in patient values and preferences when deciding on a conditional recommendation, rather than a strong recommendation, against nirmatrelvir-ritonavir.
• Given considerations regarding resources and equity, the GDG concluded that health care systems may reasonably not offer this drug to patients at low risk of hospitalization.

Practical info Given the conditional recommendation against using nirmatrelvir-ritonavir for patients with non-severe COVID-19 at low risk of hospitalization, practical considerations were felt to be less relevant here. See practical info for use of nirmatrelvir-ritonavir in patients with COVID-19 at high and moderate risks of hospitalization if needed.